Stocks and Investing Stocks and Investing
Tue, April 19, 2022
Mon, April 18, 2022

Mohit Bansal Upgraded (BIIB) to Buy and Increased Target to $265 on, Apr 18th, 2022


Published on 2024-10-27 20:29:24 - WOPRAI, Mohit Bansal
  Print publication without navigation


Mohit Bansal of Wells Fargo, Upgraded "Biogen Inc." (BIIB) to Buy and Increased Target from $235 to $265 on, Apr 18th, 2022.

Mohit has made no other calls on BIIB in the last 4 months.



There are 17 other peers that have a rating on BIIB. Out of the 17 peers that are also analyzing BIIB, 10 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $219 on, Tuesday, April 12th, 2022
  • Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $225 on, Monday, March 28th, 2022
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $223 on, Tuesday, March 8th, 2022
  • Evan Seigerman of "BMO Capital" Downgraded from Buy to Hold and Decreased Target to $238 on, Friday, February 4th, 2022
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $202 on, Thursday, January 13th, 2022
  • Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $207 on, Wednesday, January 12th, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $195 on, Wednesday, January 12th, 2022
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $216 on, Wednesday, January 12th, 2022
  • Cory Kasimov of "JP Morgan" Maintained at Hold with Decreased Target to $276 on, Tuesday, December 21st, 2021
  • Brian Skorney of "Baird" Maintained at Hold with Decreased Target to $258 on, Tuesday, December 21st, 2021


These are the ratings of the 7 analyists that currently disagree with Mohit


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $283 on, Tuesday, April 12th, 2022
  • Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $240 on, Friday, April 8th, 2022
  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $262 on, Friday, April 8th, 2022
  • Brian Abrahams of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $248 on, Thursday, March 3rd, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $305 on, Monday, February 7th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $300 on, Monday, January 24th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $270 on, Tuesday, January 18th, 2022
Contributing Sources